TABLE 5.
Allogeneic stem cell transplantation outcomes for patients with blast phase CML 1990–2018
| References | Dates of study | No. of patients | 3‐year OS (%) | 3‐year PFS (%) | Relapse incidence (%) | Non‐relapse mortality (%) |
|---|---|---|---|---|---|---|
| 65 , a | 2000–2009 | 63 | 36 | 23 | 40 | 33 |
| 63 | 1999–2004 | 80 (active BP‐CML) | 14 | 10 | 36 | 54 |
| 64 | 2004–2016 | 170 | 39 | 26 | 51 | 23 |
| 62 , b | 1990–2018 | 147 (incl. 51 AP‐CML) | 34 | 26 | 43 | 28 |
Abbreviations: OS, overall survival; PFS, progression‐free survival.
a
Median follow‐up since transplant 25 months.
b
Median follow‐up since transplant 15 years.